Ascendis Pharma A/S
ASND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $213,634 | $158,045 | $100,954 | $173,916 |
| % Growth | 35.2% | 56.6% | -42% | – |
| Cost of Goods Sold | $22,354 | $31,447 | $17,517 | $14,023 |
| Gross Profit | $191,280 | $126,598 | $83,437 | $159,893 |
| % Margin | 89.5% | 80.1% | 82.6% | 91.9% |
| R&D Expenses | $66,879 | $71,988 | $86,603 | $79,296 |
| G&A Expenses | $0 | $105,710 | $95,648 | $78,781 |
| SG&A Expenses | $113,404 | $105,710 | $95,648 | $78,781 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1,851 | $5,398 | $1,433 |
| Operating Expenses | $180,283 | $179,549 | $187,649 | $159,510 |
| Operating Income | $10,997 | -$52,951 | -$104,212 | $383 |
| % Margin | 5.1% | -33.5% | -103.2% | 0.2% |
| Other Income/Exp. Net | -$68,369 | $17,944 | $10,647 | -$37,767 |
| Pre-Tax Income | -$57,372 | -$35,007 | -$93,565 | -$37,384 |
| Tax Expense | $3,617 | $3,848 | $1,061 | $1,085 |
| Net Income | -$60,989 | -$38,855 | -$94,626 | -$38,469 |
| % Margin | -28.5% | -24.6% | -93.7% | -22.1% |
| EPS | -1 | -0.64 | -1.58 | -0.64 |
| % Growth | -56.3% | 59.5% | -146.9% | – |
| EPS Diluted | -1 | -0.82 | -1.58 | -0.64 |
| Weighted Avg Shares Out | 60,989 | 60,455 | 60,019 | 59,785 |
| Weighted Avg Shares Out Dil | 60,989 | 63,911 | 60,019 | 59,785 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $55,059 | $28,854 | -$66,545 |
| Interest Expense | $0 | $33,018 | $44,786 | -$56,628 |
| Depreciation & Amortization | $4,019 | $4,308 | $4,545 | $4,475 |
| EBITDA | -$53,353 | $2,319 | -$44,234 | -$37,893 |
| % Margin | -25% | 1.5% | -43.8% | -21.8% |